Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F20%3A00079461" target="_blank" >RIV/00023001:_____/20:00079461 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/20:N0000091

Result on the web

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034709/pdf/medi-99-e19119.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034709/pdf/medi-99-e19119.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MD.0000000000019119" target="_blank" >10.1097/MD.0000000000019119</a>

Result language

angličtina

Original language name

Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice

Original language description

Stent designs with ultrathin struts may further increase the procedural success of challenging lesion subsets. The objective of this study was to assess the safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stent (PF-SES) implantations in a large scale, unselected patient population.Adult patients underwent percutaneous coronary interventions (PCI) with a thin-strut PF-SES. Data from two all-comers observational studies having the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled. The accumulated target lesion revascularization (TLR) rate at 9-12 months was the primary endpoint. All dual antiplatelet therapy strategies according to the applicable guidelines were permissible.In total, 7243 patients were prospectively enrolled for PCI with PF-SES in stable coronary artery disease or acute coronary syndrome (ACS). Major risk factors in the overall cohort were diabetes (37.3%), ST elevation myocardial infarction (18.1%) and non-ST myocardial infarction (24.6%). The follow-up rate was 88.6% in the overall population. The TLR rate in the overall cohort was 2.2% whereas definite/probable stent thrombosis (ST) occurred in 0.7%. In patients with in-stent restenosis lesions, the major adverse cardiac events rate was 6.4% whereas the corresponding rate for isolated left main coronary artery (LMCA) disease was highest with 6.7% followed by patients with culprit lesions in vein bypasses (VB, 7.1%). The mortality rate in patients treated in VB lesions was highest with 5.4%, followed by the isolated LMCA subgroup (3.4%) and ACS (2.6%).PCI with PF-SES in an unselected patient population, is associated with low clinical event and ST rates. Furthermore, PF-SES angioplasty in niche indications demonstrated favorable safety and efficacy outcomes with high procedural success rates. © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Medicine

ISSN

0025-7974

e-ISSN

—

Volume of the periodical

99

Issue of the periodical within the volume

8

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

"art. no. e19119"

UT code for WoS article

000525864900016

EID of the result in the Scopus database

2-s2.0-85079749701